---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-025062"
form_type: "8-K"
ticker: "SCNX"
cik: "0001382574"
company_name: "Scienture Holdings, Inc."
filed_at: "2026-05-22T21:00:37+00:00"
generated_at: "2026-05-22T21:05:09.660714+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# SCIENTURE Q1 revenue $56k (+449% YoY); gross margin 95.6%; net loss $3.4M; secures $11M debt

## Summary
- Revenue $56k (+449% YoY); gross profit $54k (+7,900%); gross margin 95.6% vs 6.6%.
- Net loss $3.4M vs $3.1M; operating expenses flat at ~$3.56M.
- USPTO granted third patent for Arbli (losartan) extending exclusivity through 2041; REZENOPY got Orange Book patent.
- GPO agreements for REZENOPY covering 5,000+ institutions; sales force starts June 1, 2026.
- Secured $11M non-dilutive debt financing to support commercialization and R&D pipeline.

## SEC filing metadata
- accession: 0001493152-26-025062
- form_type: 8-K
- ticker: SCNX
- cik: 0001382574
- company_name: Scienture Holdings, Inc.
- filed_at: 2026-05-22T21:00:37+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1382574/000149315226025062/0001493152-26-025062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1382574/000149315226025062/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-025062
- JSON: https://secwatch.observer/filing/0001493152-26-025062.json
- Plain text: https://secwatch.observer/filing/0001493152-26-025062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.